Our Strategic Roadmap has four pillars which lay out the steps to achieving Vision 2025. We will focus on Values, People, R&D, and Business Performance as they will help us to progress toward Vision 2025. They need to be reviewed regularly to track progress and make sure we stay on the path to Vision 2025. We set clear goals, plans and KPIs to serve the needs of our patients, wherever they are, and to earn the trust of society and our customers.
Takeda-ism (Integrity, Fairness, Honesty, Perseverance) and the four priorities (Patient, Trust, Reputation, Business) are deeply ingrained in our ways of working to ensure our commitment to quality and that we do the right thing - at all times.
Takeda is building a patient-centric and customer-centric organization. Our local organizations are empowered to respond in the best way to customer needs.
Our employees have the possibility to develop and thrive in a diverse and agile organization.
Takeda leaders demonstrate strategic thinking, find innovative ways to serve patients, build trust with society, reinforce our reputation, and grow the business. They create an environment that inspires and enables people to collaborate and move the organization forward. They focus on our few designated priorities and deliver superior results. And they elevate the capabilities of our organization now and for the future.
Takeda has a focused, world-class R&D innovation engine, making an impact on patients' lives by translating science into life-changing medicines. We focus our research efforts on oncology, gastroenterology (GI), and central nervous system (CNS) therapeutic areas where we want to be at the cutting edge of innovation.
We also have exciting late-stage vaccine candidates for dengue and norovirus, and early research programs in specialty cardiovascular diseases. We conduct research both internally and externally, with the ambition to be considered among the best partners in the industry.
Takeda is sustaining sales growth through its portfolio in gastroenterology and oncology worldwide, and our business in Emerging Markets. We are also financially disciplined to deliver profitable growth while at the same time aiming to provide the broadest possible access to our medicines.